ClinicalTrials.gg
Active, not recruitingNCT05840822Updated Jun 30, 2026

Evaluating Efficacy and Safety of CBD TPM Capsules for Use in Insomnia

A Phase 3 interventional study of Cannabidiol (CBD) Capsule 75mg and Placebo in Insomnia, sponsored by Avecho Biotechnology. Active, not recruiting at 5 sites in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-30.

Sponsored by Avecho Biotechnology · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
519
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies in Sleep Initiation and Maintenance Disorders with a site in Australia — 9 open to participants now, 10 under way, 1 of them phase 3. Sleep Initiation and Maintenance Disorders · Australia.

Planned enrollment
9th of 25
519 · median 270
Started
2024
the only one that year
Phase 3
10 of 25
none open now
Registered
15th of 25
by date
Lead sponsor
1 of 25
Avecho Biotechnology

Among the 25 studies in Sleep Initiation and Maintenance Disorders with a site in Australia, this one is the 9th largest by planned enrollment, is the only one that started in 2024, is one of 10 in phase 3, and was the 15th registered.

Sleep Initiation and Maintenance Disorders

2,729 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 731 are open to participants now.

Browse Sleep Initiation and Maintenance Disorders studies →

Open to participants now

9 of the 25 studies in Sleep Initiation and Maintenance Disorders with a site in Australia are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 390 Sleep Initiation and Maintenance Disorders studies recruiting now, 153 (39%) set no upper age limit and 207 (53%) stop at 75 or younger; 59 take children under 18; 109 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Sleep Initiation and Maintenance Disorders with a site in Australia, or all of them as a file.
02

Study summary

Insomnia is a common sleep disorder in which a person has difficulty falling asleep or staying asleep or getting good quality sleep. Consequences of insomnia include daytime sleepiness, poor memory function, decline in concentration with negative impacts on social and work activities. Although medical cannabis and cannabis products are widely used worldwide for the management of symptoms associated with insomnia, there is little clinical data available to support the efficacy or utility of CBD in the management of sleep disorders. The proposed study will assess whether nightly doses of 75mg or 150mg of an 8 week period are able to improve patient reported sleep quality when compared to a placebo.

03

Conditions studied

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males and females aged 18 years or older at the time of .
  2. Stated willingness to comply with all study procedures and availability for the duration of the study.
  3. Provide a signed and dated patient information and consent form (PICF) for the study.
  4. Met the , Fifth Edition (DSM-5) criteria for insomnia disorder, as follows:

    • Complained of dissatisfaction with night-time sleep in the form of difficulty getting to sleep, difficulty staying asleep and/or awakening earlier in the morning than desired despite adequate opportunity for sleep.
    • Frequency of the complaint ≥3 times per week.
    • Duration of complaint ≥3 months.
    • Associated with a complaint of daytime impairment.
  5. History of subjective Sleep Onset Latency (sSOL) ≥30 minutes on at least 3 nights per week in the previous 4 weeks AND/OR subjective Wake After Sleep Onset (sWASO) ≥30 minutes on at least 3 nights per week in the previous 4 weeks.
  6. Subject reports a regular time spent in bed, either sleeping or trying to sleep is between 7-10 hours.
  7. Subjects must have clinical insomnia symptoms as classified by an insomnia severity index (ISI) Score of ≥15.
  8. Confirmation of current insomnia symptoms as determined from the Sleep Diary completed on at least 7 consecutive mornings (minimum 5 of 7 for eligibility), such that sSOL ≥30 minutes on at least 3 of the 7 nights and/or sWASO ≥30 minutes on at least 3 of the 7 nights.
  9. Subject reports a typical bedtime, (defined as the time the subject attempts to sleep), between 21:00 and 01:00, and waketime, (defined as the time the subject got out of bed for the day), between 05:00 and 10:00.
  10. Subject has access to and is able to use a smart phone.
  11. Female subjects of must be abstinent or agree to use a highly effective method of for 30 days prior to Day 1, during the study, and for at least 28 days following the last dose of Product (IP). Agrees to refrain from donating eggs (ova, oocytes) (from Day 1 until 28 days following the last dose of IP).
  12. Male subjects that are not surgically sterile (i.e., vasectomy) must be abstinent or agree to use effective barrier contraception (i.e., condom) from Day 1 and for at least 28 days following the last dose of IP and agrees to refrain from sperm donation (from Day 1 until 28 days following the last dose of IP).

Exclusion criteria

Exclusion Criteria:

  1. Significant insomnia caused during another sleep-wake disorder, including narcolepsy, a breathing-related sleep disorder, a circadian rhythm sleep-wake disorder, a parasomnia, restless leg syndrome, or an exclusionary score on the Sleep Disorders Screening Battery, or Epworth Sleepiness Scale score as follows:

    • STOP-Bang score ≥5.
    • International Restless Legs Scale score ≥16.
    • Epworth Sleepiness Scale score >15 (scores of 11-15 required excessive daytime sleepiness to be recorded in subject's medical history).
  2. Reports symptoms potentially related to narcolepsy that in the clinical opinion of the Investigator indicates the need for referral for a diagnostic evaluation for the presence of narcolepsy.
  3. Reports a history of sleep-related violent behavior, or sleep driving, or any other complex sleep-related behavior, e.g., making phone calls, or preparing and eating food while asleep.
  4. Beck Depression Inventory - (BDI II) score >19 at Screening.
  5. Beck Anxiety Inventory >15 at Screening.
  6. Habitually napped more than three times per week.
  7. Current or recent cannabis use, within 30 days of consent, and throughout the study.
  8. Use of any drug known to affect sleep, within 30 days of Screening and throughout the study, including:

    • Sedatives (e.g. benzodiazepines, zopiclone, eszopiclone, zaleplon, zolpidem, agomelatine, suvorexant, dual orexin receptor antagonists, sodium oxybate mirtazipine (sedating SSRI) and all tricyclic antidepressants,, , sedating H antihistamines (cyproheptadine, dexchlorpheniramine, promethazine, trimeprazine, doxylamine, diphenhydramine, cyclizine),, antipsychotics, melatonin, valerian).
    • Opioids (e.g. morphine, codeine, oxycodone, methadone, buprenorphine, fentanyl, tramadol, tapentadol, hydromorphone).
    • Stimulants (e.g. modafinil, methylphenidate, dexamphetamine, phentermine).
  9. Have care responsibilities for an infant \<1 year of age.
  10. Females who are pregnant or lactating.
  11. Have excessive caffeine use (>300 mg or \~3 cups of caffeinated beverages a day) that, in the opinion of the Investigator, contributes to the subject's insomnia, and is unwilling to forgo caffeine-containing beverages for the duration of their participation in the study. Any caffeine consumed needs to be prior to 4:00 pm.
  12. PI determined excessive history of acute or severe bronchial asthma (excluding childhood or exercise induced asthma), diagnosed obstructive sleep apnea, hypoxia, hypoxemia, hypercarbia, or other obstructive airway disease or any condition that may increase the risk for respiratory depression.
  13. History of neurologic conditions such as seizures or convulsive disorders (including epilepsy), severe head injury or increased intracranial pressure.
  14. A calculated of \< 85 mL/minute at Screening according to the equation using Cockcroft and Gault.
  15. Liver function tests for or aspartate aminotransferase > 1.5 times the at Screening.
  16. History of (in the opinion of the Investigator) other cardiovascular, pulmonary, neurologic or renal disorders or hepatic, gastrointestinal, oral (difficulty swallowing / taking oral medication), hematological, endocrine, or psychiatric impairment/disorders.
  17. Use of any over the counter product, or other medicine derived from hemp or containing cannabidiol, within 30 days of Screening and for duration of study.
  18. Known intolerance, allergy or reactions to cannabis or cannabinoid products (e.g. hemp), and of the IP.
  19. Currently taking or have taken drugs that are moderate or strong inhibitors of or CYP2C19 within 2 weeks or 5 half-lives, whichever is longer, prior to randomisation.
  20. Excessive use of alcohol (i.e. drink more than 2 standard units of alcohol per day or >8 standard units per week), including positive results for the alcohol breath test at Screening, Compliance Check, and Run-in/Randomization (Baseline) visits or is unwilling to abstain from alcohol consumption within 3 hours before bedtime for the duration of their participation in the study.
  21. Recreational drug use, including positive results for the urine drugs of abuse test during at Screening, Compliance Check and Run-in/Randomization (Baseline) visits.
  22. Use of any drug or involvement in another clinical trial within 30 days of Screening.
  23. Use of anti-coagulant drugs such as warfarin or those known to be metabolized by CYP450 enzymes, within 30 days of Screening.
  24. Use of treatments for insomnia (e.g. cognitive-behavioral therapy and Central Nervous System-active drugs), within 30 days of Screening.
  25. Self-reported or physician diagnosed comorbid nocturia resulting in frequent (>2) need to get out of bed to use the bathroom during the night.
  26. Any history of a medical or psychiatric condition that, in the opinion of the Investigator, may affect the subject's safety or interfere with the study assessments.
  27. Scheduled for major surgery during the study.
  28. Shift work, jet lag or trans-meridian travel (three time zones) in the past month, at Screening and while on study.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
519 participants (estimated)

Study arms

  • Placebo comparator
    Placebo

    Nightly dose of two placebo capsules

    Drug: Placebo

  • Experimental
    75mg CBD

    Nightly dose of one 75mg CBD capsule and one placebo capsule

    Drug: Cannabidiol (CBD) Capsule 75mg · Drug: Placebo

  • Experimental
    150mg CBD

    Nightly dose of two 75mg CBD capsules

    Drug: Cannabidiol (CBD) Capsule 75mg

Interventions

06

What researchers measure

Primary outcomes

  1. Mean change from study baseline of insomnia severity index (ISI) score at 8 weeks

    The insomnia severity index (ISI) is a seven-item self-report questionnaire used to assess the severity of the insomnia disorder. Total score ranges from 0-28. 0 - 7 No clinically significant insomnia. 8 - 14 Subthreshold insomnia. 15 - 21 Clinical insomnia (moderate severity) 22 - 28 Clinical insomnia (severe)

    Time frame: 8 weeks

  2. Mean change from study baseline in subject sleep efficiency (sSE) at 8 weeks

    Time frame: 8 weeks

07

Study locations

5 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Sep 2027, 40 months after the start.

Of 29 industry-sponsored phase 3 interventional studies under Sleep Initiation and Maintenance Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 25. This study's planned 40 months is above that.

Counting every sponsor, half of 42 studies reached it within 19 months; a quarter within 15 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2023
First posted
May 3, 2023
StartActual
May 16, 2024
Primary completionEst.
Sep 30, 2027
CompletionEst.
Dec 2027
Last update
Jun 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05840822
Lead sponsor
Avecho Biotechnology
Responsible party
Sponsor
First posted
May 3, 2023
Start date
May 16, 2024
Primary completion
Sep 30, 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Jun 30, 2026

Study contacts

Darren Mansfield
principal investigator · Monash Health

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cannabidiol

Start the discussion